Analyst Rating In Review: Myriad Genetics Bid Up 6.4% Since Downgraded 7 Days Ago (MYGN)
August 18, 2016 at 01:03 AM EDT
A week ago, Wells Fargo downgraded Myriad Genetics from Outperform to Market Perform. Myriad Genetics shares are selling at $20.96, 6.4% above the $19.70 price point of one week...
